Earnings call transcript: Ardelyx Q2 2025 beats earnings expectations

Ardelyx (ARDX) reported a strong Q2 2025, significantly exceeding revenue and earnings expectations with total revenue of $97.7 million, up 33% year-over-year, and a narrower net loss of $0.08 per share. This outperformance was driven by robust sales of IBSRELA, which surged 84% year-over-year to $65 million, and continued growth from EXPOSA. The company subsequently raised its full-year IBSRELA revenue guidance to $250-$260 million, signaling confidence in sustained product demand and its path to cash flow breakeven, reinforcing analyst views of potential undervaluation despite a modest 1.39% after-hours stock increase.

Analysis

Ardelyx, Inc. (ARDX) delivered a robust second quarter for 2025, significantly outperforming analyst expectations on both revenue and earnings. The company reported total revenue of $97.7 million, a 33% year-over-year increase that surpassed forecasts by 18.41%, and a net loss of $0.08 per share, which was a 38.46% positive surprise compared to the expected $0.13 loss. The primary growth driver was the impressive momentum of its IBS-C drug, IBSRELA, which saw net sales surge 84% year-over-year to $65 million, prompting management to raise its full-year guidance for the product to $250-$260 million. This performance validates the company's strategy of expanding its sales force and improving market access. Concurrently, its hyperphosphatemia drug, EXPOSA, demonstrated resilience by posting $25 million in sales—a 27% quarter-over-quarter increase when excluding a one-time reserve release in Q1—successfully navigating a challenging new market environment following the loss of Medicare as a payer. The company's financial position appears strong, with a current ratio of 4.12 and $238.5 million in cash, and the recent completion of its royalty obligation to AstraZeneca is poised to benefit future gross margins. However, risks remain, including the departure of the CFO, rising SG&A expenses projected to hit $90 million quarterly, and the ongoing transition for EXPOSA. The modest 1.39% after-hours stock appreciation suggests the market may be waiting for further confirmation of sustained profitability, despite analyst price targets ($8-$15) indicating significant potential undervaluation relative to its $4.33 closing price.

Key Decisions for Investors

• Investors should recognize the strong execution on IBSRELA as the core value driver, with the raised full-year guidance of $250-$260 million serving as a critical benchmark for continued momentum.
• It is prudent to closely monitor EXPOSA's sequential revenue growth and the impact of rising SG&A expenses on the company's path to cash flow breakeven, which management suggests is on the near-term horizon.
• Key upcoming catalysts to watch include any announcements regarding a potential EU partnership and the outcome of the CMS legal proceedings, which have oral arguments scheduled for September 25.
• Given the significant disconnect between the strong quarterly performance, positive analyst consensus, and the muted stock reaction, investors may consider the current valuation an opportunity, contingent on the company's ability to maintain its growth trajectory and manage expenses effectively.